TAG Expands Its End the Epidemic Campaign to Include Southern States Heavily Impacted by HIV
A new initiative is under way to strengthen community leadership and mobilization toward ambitious HIV prevention and treatment goals against the backdrop of anticipated shifts in federal support and resources for critical programs. NEW YORK, NY, January 30, 2017—Treatment Action Group (TAG) is pleased to announce the expansion of its Ending the Epidemic campaign to foster the development of bold epidemic-ending initiatives in some of the most heavily impacted regions of the United States. In close collaboration with its national and regional partners, TAG aims to strengthen partnerships in three southern states to substantially reduce HIV incidence and maximize health outcomes, and to support the community mobilization efforts required to foster the federal and regional political support necessary to meet established goals.
Read more »
UC Berkeley School of Public Health: Online Education News
A message from Dean Stefano Bertozzi and the UC Berkeley School of Public Health.
Are you or someone you know looking to expand your skills or brush up on a certain area of public health? The School of Public Health On-Campus/Online MPH degree program—the first online professional degree program offered at UC Berkeley—has been very successful to date and we’ve recently added a track in Health Policy and Management. Now, we are taking our online education further by offering more degree concentrations and introducing single course and certificate enrollment options.
In the coming months we will be introducing new Public Health Certificates to complement our already popular online MPH degree. These certificates—composed of 3 or 4 specialized courses—will focus on specific areas such as Global Health, Geographic Information Systems, Health Management, Leadership and Innovation, and Epidemiology and Biostatistics.
Starting in January 2017, we are introducing single courses available for immediate enrollment, with a few more courses starting in March 2017. We appreciate your support in spreading the word about these online courses. If you or someone you know might be interested, please see below to get started.
Read more »
Singapore Hepatitis Conference: Meeting Materials
The Singapore Hepatitis Conference was convened on 27-28 May 2016 in Singapore. With more than 400 participants representing 26 countries, the meeting successfully created awareness, provided updates, and shared new developments in the clinical management of HBV and HCV.
Read more »
National Institute of Allergy and Infectious Diseases: Progress Toward an HIV Vaccine Video
A message from the NIH National Institute of Allergy and Infectious Diseases (NIAID).
The NIAID has posted a video describing the development of HIV vaccine candidates and the launch of the NIAID-supported HVTN 702 clinical trial, the first new HIV vaccine efficacy study in seven years. HVTN 702 is testing whether an experimental vaccine regimen safely prevents HIV infection among South African adults. The regimen involves a new version of the only HIV vaccine candidate ever shown to provide some protection against the virus.
Read more »
HIVMA Medical Students Program
The HIVMA medical program supports HIV-related clinical learning, research projects and mentor relationships for students at accredited U.S. medical schools. Selected medical students receive free HIVMA/IDSA membership, a $3,500 stipend per year for up to three years, and have flexibility in designing curriculum to complement their schools' curriculum and training, dependent on successfully meeting annual milestones. The program provides an additional $1,000 for mentors and institutions for incidental expenses including supplies and conference registration. First, second and third year students are eligible to apply. Mentors must be HIVMA members, and must demonstrate a commitment to student mentorship for the duration of the grant. The 2017 application deadline is February 15.
Read more »
HHS: Viral Hepatitis Action Plan Updates & Request for Support
A message from the Office of HIV/AIDS and Infectious Disease Policy, Office of the Assistant Secretary for Health, Department of Health and Human Services (HHS).
Rich Wolitski, Director Corinna Dan, Viral Hepatitis Policy Advisor
We write for two reasons, to update you on our progress in developing and releasing the National Viral Hepatitis Action Plan for 2017 - 2020 and to ask for you to help us raise awareness of the HHS.gov/hepatitis website.
As you may recall, last April our federal partners met and agreed to develop an updated National Viral Hepatitis Action Plan (NVHAP). Since that time, we have worked with the 23 federal partners that compose the Viral Hepatitis Implementation Group. We have also worked diligently to capture key issues identified by our nonfederal partners. Although the process has been time intensive, the result will be an evidence-based, responsive road map for the nation to combat hepatitis B and hepatitis C for 2017 – 2020. The new NVHAP will identify measurable, aspirational 2020 goals and annual targets that will need to be met or exceeded if we are to achieve our goals.
Read more »
EATG Press Release: Romania hosts Policy Meeting of AHIV/AIDS advocates from across Europe
PRESS RELEASE Bucharest, 06 November 2016
The European AIDS Treatment Group (EATG –www.eatg.org) has chosen the Romanian capital Bucharest as place for its autumn 2016 Policy Meeting. The entire region of Central and Eastern Europe, and Central Asia face particular problems that require specific responses form the communities of people living with HIV.
By holding our meeting in Bucharest and inviting Romanian organisations we want to underline our commitment to people living with HIV and at risk of HIV infections in the region. We also want to highlight the need to ensure that the AIDS response – in terms of both prevention and treatment – is fully funded, because without that we can only expect to see an increase in even more costly new infections.
Read more »
The IAS is Calling for 2017 Abstract Mentors
A message from the International AIDS Society (IAS).
Help build the next generation of researchers and scientists. The International AIDS Society’s (IAS) Abstract Mentor Programme connects young and early career researchers with experienced researchers in the field of HIV, giving them a rare opportunity to receive constructive feedback on their abstracts before submitting them for the 9th IAS Conference on HIV Science (IAS 2017).
Read more »
Scientists at NIH and Emory Achieve Sustained SIV Remission in Monkeys
NIH Clinical Trial of Treatment Regimen in HIV-Infected People is Underway.
Scientists at the National Institutes of Health (NIH) and Emory University have experimentally induced sustained remission of SIV, the simian form of HIV, in infected monkeys. The animals’ immune systems have been suppressing the virus to undetectable levels for as long as 23 months since the monkeys completed an investigational treatment regimen. In addition, the regimen has led to the near-complete replenishment of key immune cells that SIV had destroyed, something unachievable with antiretroviral therapy (ART) alone. The findings will be published in the Oct. 14 issue of the journal Science.
“Our data suggest that the immune systems of these animals are controlling SIV replication in the absence of antiretroviral therapy,” said Anthony S. Fauci, M.D., who co-led the study as chief of the Laboratory of Immunoregulation at the National Institute of Allergy and Infectious Diseases (NIAID), part of NIH. “The experimental treatment regimen appears to have given the immune systems of the monkeys the necessary boost to put the virus into sustained remission. The precise mechanisms of this effect are unclear and will be actively pursued since they could have important implications for the control of HIV infection in humans in the absence of ART. At this point it is also unclear whether the findings of the newly reported animal study will translate into a clinical benefit for HIV-infected people.” Dr. Fauci also is director of NIAID, the primary funder of the research.
Read more »
Funding Opportunity Title: HIV, HCV and Related Comorbidities in Rural Communities Affected by Opioid Injection Drug Epidemics in the United States: Building Systems for Prevention, Treatment and Control (UG3/UH3)
A message from the National Institute on Drug Abuse (NIDA) and partner components and agencies.
NIDA and partner components and agencies intend to commit an estimated total of $6.5 Million in FY2017 to fund 8-10 UG3 awards. Future year amounts will depend on annual appropriations and successful completion of UG3 study benchmarks that permit continuation to the UH3 award. It is anticipated that 6-8 UH3 awards will be funded.
Funds Available and Anticipated Number of Awards
Read more »
|
|